Navigation Links
Are research participants safe enough?
Date:4/26/2010

Every year, millions of patients worldwide participate in randomized clinical trials hoping to benefit from an experimental treatment or potentially help someone else with the same condition.

However, rules and regulations are becoming a menace to academic clinical trials where resources are limited and risks may be much less than those associated with new experimental drugs.

"There is no question that research participants need protection," write Paul Hbert, Editor-in-Chief, CMAJ, and coauthors. "But regulations have grown so burdensome that they are overwhelming the very things they are meant to support and safeguard. Consequently, clinical research has been substantially decreased among industrialized countries."

International bodies, regulatory authorities, the academic community and major granting agencies need to work together to develop and adopt proper, study-specific standards instead of having ineffective monitoring of all clinical research.

The authors conclude that without significant changes, our academic research enterprise and eventually even commercial trials will be immobilized by increasing bureaucracy and spiraling costs.


'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Source:Eurekalert

Page: 1

Related medicine news :

1. Scientific meeting will host new research in childrens ear, nose and throat health
2. Los Angeles Plastic Surgeon is the New President of the Aesthetic Surgery and Research Foundation (ASERF)
3. Cancer research award to Johns Hopkins basic scientist
4. Parkinson's Disease Patient's Story Goes Multimedia, Proceeds to Benefit PD Research
5. Nutrition researchers to develop new growth charts for children with Down syndrome
6. MU researchers show potential for new cancer detection and therapy method
7. Provalis Research Announces the Release of WordStat 6, Delivering Enhanced Analytical and Visualization Tools for Textual Data
8. Researchers successfully lower radiation dose associated with pediatric chest CT scans
9. Researchers identify a new breast and ovarian cancer susceptibility gene
10. Researchers show that nitric oxide-donating naproxen can boost colorectal cancer prevention
11. Lombardi research teams hone in on treatments for osteosarcoma and Ewings sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... Conference from Sept. 18 to 20. , The two-day conference is focused on ... the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. The ...
(Date:6/23/2017)... ... , ... Ross Insurance Agency ( http://www.rossinsuranceagency.com ) saves clients ... (FEMA) recent update of flood zones, more people than ever are in flood ... to reflect the actual risk in flood zone areas during a time when ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance Services, ... communities in the greater Chicago metropolitan area, is embarking on a charity drive ... in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of the ...
(Date:6/22/2017)... FL (PRWEB) , ... June 22, 2017 , ... Branches, ... received more than $245,000 in grant funding to support its programs focused on providing ... Branches, Inc. was awarded a grant by the Foundation of $15,000 to support its ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National Health System ... (AHA) to launch a Rheumatic Heart Disease Center, with the goal of developing ... heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities across the ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that the U.S. Food and Drug Administration ... June 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning ... manufacturing facility is a measure of the progress we ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
Breaking Medicine Technology: